

HR 2880

Protecting Patients Against PBM Abuses Act

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 26, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 17, 2024)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/2880>

Sponsor

Name: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (45 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Auchincloss, Jake [D-MA-4]	D · MA		Apr 26, 2023
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Apr 26, 2023
Rep. Malliotakis, Nicole [R-NY-11]	R · NY		Apr 26, 2023
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Jun 30, 2023
Rep. Miller-Meeks, Mariannette [R-IA-1]	R · IA		Jul 26, 2023
Rep. Dunn, Neal P. [R-FL-2]	R · FL		Aug 25, 2023
Rep. Ross, Deborah K. [D-NC-2]	D · NC		Aug 25, 2023
Rep. Carl, Jerry L. [R-AL-1]	R · AL		Sep 13, 2023
Rep. Mann, Tracey [R-KS-1]	R · KS		Sep 22, 2023
Rep. Ferguson, A. Drew, IV [R-GA-3]	R · GA		Oct 30, 2023
Rep. Harshbarger, Diana [R-TN-1]	R · TN		Nov 8, 2023
Rep. Allen, Rick W. [R-GA-12]	R · GA		Nov 28, 2023
Rep. Miller, Carol D. [R-WV-1]	R · WV		Jan 10, 2024
Rep. Valadao, David G. [R-CA-22]	R · CA		Mar 19, 2024
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Apr 15, 2024
Rep. Sherrill, Mikie [D-NJ-11]	D · NJ		Apr 23, 2024
Rep. Barragán, Nanette Diaz [D-CA-44]	D · CA		May 7, 2024
Rep. Cherfilus-McCormick, Sheila [D-FL-20]	D · FL		May 7, 2024
Rep. Scott, Austin [R-GA-8]	R · GA		May 7, 2024
Rep. Davis, Donald G. [D-NC-1]	D · NC		May 16, 2024
Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]	R · TN		May 21, 2024
Rep. Hudson, Richard [R-NC-9]	R · NC		May 21, 2024
Rep. Cartwright, Matt [D-PA-8]	D · PA		May 22, 2024
Rep. Jackson, Jonathan L. [D-IL-1]	D · IL		May 22, 2024
Rep. Vasquez, Gabe [D-NM-2]	D · NM		Jun 3, 2024
Rep. Spanberger, Abigail Davis [D-VA-7]	D · VA		Jun 11, 2024
Rep. Salinas, Andrea [D-OR-6]	D · OR		Jun 12, 2024
Rep. McCormick, Richard [R-GA-6]	R · GA		Jun 18, 2024
Rep. Lawler, Michael [R-NY-17]	R · NY		Jun 25, 2024
Rep. Grothman, Glenn [R-WI-6]	R · WI		Jun 26, 2024
Rep. Caraveo, Yadira [D-CO-8]	D · CO		Jul 22, 2024
Rep. Rose, John W. [R-TN-6]	R · TN		Jul 22, 2024
Rep. Flood, Mike [R-NE-1]	R · NE		Jul 23, 2024
Rep. Levin, Mike [D-CA-49]	D · CA		Jul 23, 2024
Rep. LaLota, Nick [R-NY-1]	R · NY		Jul 30, 2024
Rep. Kiggans, Jennifer A. [R-VA-2]	R · VA		Aug 2, 2024
Rep. James, John [R-MI-10]	R · MI		Aug 13, 2024
Rep. Krishnamoorthi, Raja [D-IL-8]	D · IL		Sep 9, 2024
Rep. Van Orden, Derrick [R-WI-3]	R · WI		Sep 9, 2024
Rep. Smucker, Lloyd [R-PA-11]	R · PA		Sep 19, 2024
Rep. Garcia, Mike [R-CA-27]	R · CA		Oct 4, 2024

Cosponsor	Party / State	Role	Date Joined
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Oct 11, 2024
Rep. Tenney, Claudia [R-NY-24]	R · NY		Oct 11, 2024
Rep. Nickel, Wiley [D-NC-13]	D · NC		Nov 1, 2024
Rep. Menendez, Robert [D-NJ-8]	D · NJ		Nov 18, 2024

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Nov 15, 2023
Ways and Means Committee	House	Referred to	Dec 17, 2024

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 26, 2023)

Protecting Patients Against PBM Abuses Act

This bill establishes requirements for Medicare pharmacy benefit managers (PBMs) with respect to remuneration, payments, and fees.

Specifically, the bill restricts PBMs that are under contract with plans under the Medicare prescription drug benefit or Medicare Advantage from (1) receiving income for their services other than flat dollar amount service fees; (2) basing any service fees on the prices of covered drugs or any associated discounts, rebates, or other remuneration; (3) charging plan sponsors for ingredient costs or dispensing fees in amounts that are different than what is reimbursed to the pharmacy; or (4) reimbursing network pharmacies for less than that what is reimbursed to PBM-affiliated pharmacies.

Such PBMs must also report on the difference between certain costs for drugs on the plan's formulary and those that are not on the formulary but are therapeutically equivalent. PBMs must also report certain information regarding rebates and fees they receive from drug manufacturers; the Centers for Medicare & Medicaid Services must publish this and other information that is currently reported by PBMs online.

Actions Timeline

- **Dec 17, 2024:** Referred to the Subcommittee on Health.
- **Dec 6, 2023:** Committee Consideration and Mark-up Session Held
- **Dec 6, 2023:** Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
- **Dec 5, 2023:** Committee Consideration and Mark-up Session Held
- **Nov 15, 2023:** Subcommittee Consideration and Mark-up Session Held
- **Nov 15, 2023:** Forwarded by Subcommittee to Full Committee by Voice Vote.
- **Apr 28, 2023:** Referred to the Subcommittee on Health.
- **Apr 26, 2023:** Introduced in House
- **Apr 26, 2023:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.